|
|
Volumn 13, Issue 2, 2012, Pages 128-130
|
|
NICE guidance on rituximab for first-line treatment of symptomatic stage III-IV follicular lymphoma in previously untreated patients.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
RITUXIMAB;
CANCER STAGING;
COST BENEFIT ANALYSIS;
FOLLICULAR LYMPHOMA;
HEALTH CARE DELIVERY;
HUMAN;
NOTE;
ORGANIZATION AND MANAGEMENT;
PATHOLOGY;
PRACTICE GUIDELINE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SURVIVAL;
UNITED KINGDOM;
ANTIBODIES, MONOCLONAL, MURINE-DERIVED;
ANTINEOPLASTIC AGENTS;
COST-BENEFIT ANALYSIS;
DELIVERY OF HEALTH CARE;
GREAT BRITAIN;
HUMANS;
LYMPHOMA, FOLLICULAR;
NEOPLASM STAGING;
PRACTICE GUIDELINES AS TOPIC;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SURVIVAL ANALYSIS;
MLCS;
MLOWN;
|
|
EID: 84858381626
PISSN: None
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/s1470-2045(12)70009-8 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
